Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04176731 · ClinicalTrials.gov registry record · NA
Prepivotal Omnipod Horizon™ Automated Glucose Control System
A NA study, sponsored by Insulet Corporation.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT04176731: Completed NA study, sponsored by Insulet Corporation.
NCT04176731 is a NA study that has completed, run by Insulet Corporation. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04176731, a NA study, has completed, sponsored by Insulet Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 14-day hybrid closed-loop phase conducted in both a hotel/rental house setting and outpatient setting.
Primary Outcome
Measure of serious device-related adverse events
Interventions
- DEVICE Omnipod Horizon™ Automated Glucose Control System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-12-15 |
| Est. Completion | 2020-01-31 |
| Phase | NA |
What the finished NCT04176731 record still lists
NCT04176731 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Omnipod Horizon™ Automated Glucose Control System is the first listed.
NCT04176731 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04176731 about?
NCT04176731 is a clinical study titled "Prepivotal Omnipod Horizon™ Automated Glucose Control System". Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 14-day hybrid closed-loop phase conducted in both a hotel/rental house setting and outpatient setting.
What is the current status of trial NCT04176731?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2019-12-15. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT04176731?
The interventions under investigation include: Omnipod Horizon™ Automated Glucose Control System (DEVICE).
Who is sponsoring clinical trial NCT04176731?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04176731's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI